The anti-inflammatory properties of simvastatin can benefit statin-naïve rheumatoid arthritis patients with associated risks for cardiovascular disease

References

• Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol. 2008;22(4):583–604.10.1016/j.berh.2008.07.001
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.10.1056/NEJMra1004965
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–94.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Sakoda K, Yamamoto M, Negishi Y, et al. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006 Jun;85(6):520–3.10.1177/154405910608500608
   PubMed Web of Science ®Google Scholar
• Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170(3):1524–30.10.4049/jimmunol.170.3.1524
   PubMed Web of Science ®Google Scholar
• Steimle V, Siegrist CA, Mottet A, et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994 Jul 1;265(5168):106–9.10.1126/science.8016643
   PubMed Web of Science ®Google Scholar
• Kurakata S, Kada M, Shimada Y, et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology. 1996 Aug;34(1):51–61.10.1016/0162-3109(96)00108-7
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Coblyn JS. Statin therapy in rheumatoid arthritis. South Med J. 2005;98(5):534–40; quiz 541, 572.10.1097/01.SMJ.0000161755.22998.F7
   PubMed Web of Science ®Google Scholar
• Tu H, Li Q, Xiang S, et al. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis. 2012 May;222(1):29–33.10.1016/j.atherosclerosis.2012.02.023
   PubMed Web of Science ®Google Scholar
• Paraskevas KI. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol. 2008;27(3):281–7.10.1007/s10067-007-0806-8
   PubMed Web of Science ®Google Scholar
• Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–7.10.1002/art.v59:12
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 1995;38(1):38–43.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Pala O, Cavaliere LF. Joint counts. In: Bartlett SJ, editor. Clinical care in the Rheumatic Diseases. 3rd ed. Atlanta, GA: Association of Rheumatology Health Professionals; 2006. p. 39–41.
   Google Scholar
• Abud-Mendoza C, De la Fuente H, Cuevas-Orta E, et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003;12(8):607–11.10.1191/0961203303lu429oa
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Douglas KM, Saratzis AN, et al. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7(7):1–24.
   PubMedGoogle Scholar
• Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l. J Am Coll Cardiol. 2005 May 17;45(10):1644–8.10.1016/j.jacc.2005.02.080
   PubMed Web of Science ®Google Scholar
• Kanda H, Yokota K, Kubo K, et al. Simvastatin reduces the disease activity in patients with rheumatoid arthritis. Arthritis Rheum. 2004;50Suppl 9:S387.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, Van'T Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44–8.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Cojocaru L, Rusali AC, Şuţa C, et al. The role of simvastatin in the therapeutic approach of rheumatoid arthritis. Autoimmune Dis. 2013;2013:326258.
   PubMedGoogle Scholar
• Chalubinski M, Broncel M. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit. 2010;16(11):245–51.
   Google Scholar